KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Cash & Equivalents data on record, last reported at $2.5 billion in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 24.58% year-over-year to $2.5 billion; the TTM value through Sep 2025 reached $2.5 billion, up 24.58%, while the annual FY2024 figure was $2.5 billion, 8.86% down from the prior year.
  • Cash & Equivalents reached $2.5 billion in Q3 2025 per REGN's latest filing, up from $2.0 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.9 billion in Q1 2023 and bottomed at $1.4 billion in Q1 2021.
  • Average Cash & Equivalents over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 132.68% in 2022, then tumbled 42.94% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $3.4 billion in 2021, then decreased by 9.51% to $3.1 billion in 2022, then fell by 12.1% to $2.7 billion in 2023, then dropped by 8.86% to $2.5 billion in 2024, then grew by 0.73% to $2.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.5 billion in Q3 2025, $2.0 billion in Q2 2025, and $3.1 billion in Q1 2025.